The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...

Genmab plans to present full results at an upcoming medical meeting.

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...

Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

Epkinly monotherapy significantly improved progression-free survival in relapsed/refractory DLBCL patients, reducing cancer ...

Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing. He wasn’t expecting a fall during an ice storm to lead to a cancer diagnosis. But ...

"Histological transformation of FL to DLBCL was a low‐incidence event associated with distinct clinical features and inferior survivals . . . By population‐based analysis and external validation, ...

Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.

– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Compared with some other ...